X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.globenewswire.com/news-release/2023/04/04/2640246/0/en/Press-Release-Two-fitusiran-Phase-3-studies-published-in-The-Lancet-and-The-Lancet-Haematology-highlight-potential-to-address-unmet-needs-across-all-types-of-hemophilia.html
https://pharmaphorum.com/news/sanofi-trumpets-data-with-haemophilia-treatment-duo-at-isth/
https://www.biopharmadive.com/news/rebounding-from-setbacks-sanofi-reveals-promising-data-for-hemophilia-drug/611424/
https://www.globenewswire.com/news-release/2021/12/14/2351761/0/en/Data-from-two-Phase-3-studies-demonstrating-fitusiran-significantly-reduced-bleeds-in-people-with-hemophilia-A-or-B-with-or-without-inhibitors-were-featured-at-ASH-s-plenary-and-la.html
https://www.reuters.com/business/healthcare-pharmaceuticals/biontech-says-expect-more-data-new-variant-2-weeks-2021-11-26/
https://www.fiercebiotech.com/biotech/sanofi-delays-hemophilia-filing-18-months-amid-safety-concerns
https://endpts.com/sanofi-accepts-a-lengthy-delay-as-its-hemophilia-drug-fitusiran-resumes-a-phiii-after-safety-fears-forced-a-halt/
https://www.sanofi.com/en/media-room/press-releases/2020/2020-12-10-23-00-00#:~:text=Sanofi%20will%20resume%20fitusiran%20dosing,B%2C%20with%20or%20without%20inhibitors.
https://www.fiercepharma.com/pharma/alnylam-s-rnai-therapy-givlaari-shows-lasting-effect-1-year-into-treatment-new-data-show
http://www.pharmatimes.com/news/givlaari_approved_in_eu_following_recent_chmp_nudge_1328021
http://www.pharmatimes.com/news/givlaari,_nubeqa_among_jan_chmp_decisions_1323999
https://www.raps.org/news-and-articles/news-articles/2020/1/chmp-recommends-15-medicines-extends-six-indicati
https://www.fiercepharma.com/pharma/jpm-alnylam-looks-to-catalyst-rich-year-ahead-heels-givlaari-approval
https://www.raps.org/news-and-articles/news-articles/2019/11/fda-approves-5-new-costly-drugs-well-ahead-of-acti
https://www.biopharmadive.com/news/fdas-rapid-review-pace-nets-an-early-approval-for-alnylams-second-drug/567754/
https://www.fiercepharma.com/pharma/alnylam-scores-fda-approval-for-rare-liver-disease-med-givlaari
https://www.businesswire.com/news/home/20190412005455/en/Alnylam-Presents-Positive-Complete-Results-ENVISION-Phase/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
https://endpts.com/alnylam-spotlights-just-how-good-the-efficacy-data-are-for-givosiran-tamping-down-on-safety-concerns/
https://www.fiercebiotech.com/biotech/alnylam-s-givosiran-hits-mark-phase-3-porphyria-test-nda-to-follow-midyear
https://endpts.com/alnylam-shores-up-enthusiasm-for-givosiran-with-early-dataset-ahead-of-crucial-phiii-readout/
Market Place
Share 
